

0

FSGS patient at time of disease recurrence    10 healthy controls from EPIC study    FSGS patient at time of disease recurrence    10 healthy controls from EPIC study

Analyte	Metabolite class	Mean (Concentration in $\mu\text{M}$ , red FSGS> CTRL, green FSGS< CTRL)		SD	
		FSGS patient at time of disease recurrence	10 healthy controls from EPIC study	FSGS patient at time of disease recurrence	10 healthy controls from EPIC study
C0	acylcarnitines	30,93	32,72	14,40	7,07
C14:1	acylcarnitines	0,16	0,09	0,03	0,02
C18:2	acylcarnitines	0,06	0,11	0,02	0,01
C2	acylcarnitines	3,89	5,36	1,63	2,11
C3	acylcarnitines	0,33	0,39	0,07	0,08
C4	acylcarnitines	0,40	0,42	0,11	0,09
Arg	aminoacids	87,13	56,06	25,90	20,79
Gln	aminoacids	812,25	536,50	108,96	97,91
Gly	aminoacids	314,50	169,01	87,11	47,97
His	aminoacids	83,90	60,68	15,26	13,78
Met	aminoacids	33,20	21,99	8,75	5,64
Orn	aminoacids	149,00	75,02	47,24	23,79
Phe	aminoacids	75,28	54,10	16,81	9,60
Pro	aminoacids	334,25	182,32	43,22	62,33
Ser	aminoacids	150,93	81,55	44,47	16,01
Thr	aminoacids	211,90	108,25	78,01	29,21
Trp	aminoacids	56,73	51,80	11,35	9,23
Tyr	aminoacids	67,00	60,48	16,49	18,40
Orn/Arg ratio	aminoacids	1,71	1,34		
Thy/Phe	aminoacids	0,89	1,12		
lysoPC a C16:t	glycerophospholipids	155,00	61,92	47,53	16,65
lysoPC a C16::	glycerophospholipids	3,66	2,20	1,16	0,98
lysoPC a C17:t	glycerophospholipids	3,13	1,11	0,88	0,31
lysoPC a C18:t	glycerophospholipids	52,28	18,93	14,55	4,83
lysoPC a C18::	glycerophospholipids	38,68	13,82	12,37	4,52
lysoPC a C18::	glycerophospholipids	60,05	21,61	19,30	5,35
lysoPC a C20::	glycerophospholipids	4,32	1,94	1,74	0,42
lysoPC a C20::	glycerophospholipids	11,51	5,13	4,53	1,32
lysoPC a C24:t	glycerophospholipids	0,29	0,50	0,03	0,07
lysoPC a C26::	glycerophospholipids	0,27	0,13	0,06	0,03
lysoPC a C28::	glycerophospholipids	0,90	0,35	0,17	0,07
PC aa C28:1	glycerophospholipids	4,39	2,27	0,48	0,56
PC aa C30:0	glycerophospholipids	4,04	5,34	0,47	1,51
PC aa C32:0	glycerophospholipids	19,35	15,69	1,97	2,92
PC aa C32:1	glycerophospholipids	16,93	23,37	3,37	12,91
PC aa C32:2	glycerophospholipids	4,67	4,94	1,11	1,61
PC aa C32:3	glycerophospholipids	0,62	0,54	0,12	0,09
PC aa C34:1	glycerophospholipids	217,50	208,89	22,05	48,82
PC aa C34:2	glycerophospholipids	372,00	382,05	40,23	49,75
PC aa C34:3	glycerophospholipids	17,90	17,21	2,48	3,88
PC aa C34:4	glycerophospholipids	2,03	1,99	0,66	0,57

PC aa C36:0	glycerophospholipids	2,26	1,47	0,45	0,45
PC aa C36:1	glycerophospholipids	53,43	42,97	8,34	10,48
PC aa C36:2	glycerophospholipids	234,00	219,81	26,85	27,99
PC aa C36:3	glycerophospholipids	151,75	141,21	16,32	23,60
PC aa C36:4	glycerophospholipids	208,25	194,34	30,46	28,59
PC aa C36:5	glycerophospholipids	24,03	22,27	5,17	7,42
PC aa C36:6	glycerophospholipids	0,89	0,94	0,23	0,28
PC aa C38:0	glycerophospholipids	2,90	2,18	0,46	0,59
PC aa C38:1	glycerophospholipids	0,72	0,92	0,29	0,39
PC aa C38:3	glycerophospholipids	52,50	42,26	8,32	9,48
PC aa C38:4	glycerophospholipids	116,45	100,35	24,78	16,44
PC aa C38:5	glycerophospholipids	58,25	49,85	10,68	8,94
PC aa C38:6	glycerophospholipids	82,13	70,40	8,52	15,92
PC aa C40:2	glycerophospholipids	0,21	0,26	0,05	0,06
PC aa C40:3	glycerophospholipids	0,39	0,44	0,03	0,06
PC aa C40:4	glycerophospholipids	2,60	2,92	0,39	0,60
PC aa C40:5	glycerophospholipids	7,68	8,14	1,20	2,02
PC aa C40:6	glycerophospholipids	23,20	20,93	2,81	5,34
PC aa C42:0	glycerophospholipids	0,35	0,42	0,05	0,11
PC aa C42:1	glycerophospholipids	0,16	0,21	0,03	0,06
PC aa C42:2	glycerophospholipids	0,12	0,18	0,02	0,04
PC aa C42:4	glycerophospholipids	0,11	0,17	0,02	0,03
PC aa C42:6	glycerophospholipids	0,27	0,57	0,04	0,06
PC ae C30:0	glycerophospholipids	0,39	0,67	0,08	0,13
PC ae C30:2	glycerophospholipids	0,13	0,09	0,02	0,02
PC ae C32:1	glycerophospholipids	3,36	2,59	0,56	0,61
PC ae C32:2	glycerophospholipids	0,95	0,63	0,14	0,16
PC ae C34:0	glycerophospholipids	1,83	1,78	0,35	0,40
PC ae C34:1	glycerophospholipids	13,33	9,09	1,88	2,10
PC ae C34:2	glycerophospholipids	19,00	10,39	2,21	1,98
PC ae C34:3	glycerophospholipids	11,49	6,44	1,94	1,30
PC ae C36:0	glycerophospholipids	0,81	0,98	0,12	0,18
PC ae C36:1	glycerophospholipids	9,72	7,09	0,93	1,65
PC ae C36:2	glycerophospholipids	18,38	12,44	2,09	2,83
PC ae C36:3	glycerophospholipids	10,70	6,48	1,24	1,05
PC ae C36:4	glycerophospholipids	27,78	15,23	3,40	3,10
PC ae C36:5	glycerophospholipids	15,58	9,65	2,42	1,80
PC ae C38:0	glycerophospholipids	1,79	2,04	0,26	0,47
PC ae C38:1	glycerophospholipids	0,41	0,61	0,26	0,30
PC ae C38:2	glycerophospholipids	2,06	1,64	0,11	0,29
PC ae C38:3	glycerophospholipids	4,78	3,51	0,97	0,78
PC ae C38:4	glycerophospholipids	17,88	10,88	3,95	2,39
PC ae C38:5	glycerophospholipids	24,85	14,41	3,56	2,80
PC ae C38:6	glycerophospholipids	8,96	5,88	1,13	1,36
PC ae C40:1	glycerophospholipids	1,23	1,09	0,17	0,27
PC ae C40:2	glycerophospholipids	1,82	1,22	0,14	0,24
PC ae C40:3	glycerophospholipids	0,92	0,92	0,12	0,23
PC ae C40:4	glycerophospholipids	2,16	1,78	0,32	0,47
PC ae C40:5	glycerophospholipids	3,50	2,80	0,62	0,75
PC ae C40:6	glycerophospholipids	4,58	3,30	0,55	0,73

<b>PC ae C42:2</b>	glycerophospholipids	0,42	0,39	0,05	0,08
<b>PC ae C42:3</b>	glycerophospholipids	0,53	0,78	0,08	0,13
<b>PC ae C44:3</b>	glycerophospholipids	0,07	0,83	0,02	0,08
<b>PC ae C44:5</b>	glycerophospholipids	1,16	1,05	0,28	0,37
<b>PC ae C44:6</b>	glycerophospholipids	0,72	0,74	0,13	0,26
<b>SM (OH) C14:</b>	sphingolipids	8,76	6,33	1,29	1,46
<b>SM (OH) C16:</b>	sphingolipids	3,92	3,49	0,56	0,81
<b>SM (OH) C22:</b>	sphingolipids	8,71	9,84	1,24	1,70
<b>SM (OH) C22:</b>	sphingolipids	9,73	8,10	1,53	1,95
<b>SM (OH) C24:</b>	sphingolipids	0,74	0,95	0,12	0,20
<b>SM C16:0</b>	sphingolipids	109,33	115,76	15,77	14,07
<b>SM C16:1</b>	sphingolipids	18,58	15,81	2,69	2,60
<b>SM C18:0</b>	sphingolipids	24,25	22,52	3,27	5,15
<b>SM C18:1</b>	sphingolipids	11,46	10,66	1,88	2,65
<b>SM C20:2</b>	sphingolipids	0,71	0,51	0,07	0,11
<b>SM C22:3</b>	sphingolipids	5,39	0,19	1,25	0,31
<b>SM C24:0</b>	sphingolipids	13,03	15,27	1,54	1,86
<b>SM C24:1</b>	sphingolipids	36,88	35,46	4,93	5,58
<b>SM C26:0</b>	sphingolipids	0,12	0,11	0,03	0,04
<b>SM C26:1</b>	sphingolipids	0,26	0,23	0,06	0,08
<b>H1</b>	sugars	5695,25	4589,39	588,41	890,44

**Difference FSGS  
patient at time of  
disease recurrence  
versus healthy controls**

**p-Wert (red,  $p < 0,05$ )**

	8,2E-01
	1,4E-02
	8,3E-03
	1,8E-01
	1,5E-01
	7,3E-01
	9,0E-02
	9,2E-03
	4,0E-02
	4,7E-02
	7,8E-02
	4,9E-02
	8,2E-02
	1,1E-03
	5,1E-02
	7,5E-02
	4,6E-01
	5,1E-01
	2,8E-02
	8,0E-02
	1,8E-02
	1,8E-02
	2,6E-02
	2,7E-02
	7,1E-02
	6,6E-02
	9,3E-06
	1,8E-02
	6,7E-03
	6,2E-04
	5,6E-03
	2,1E-02
	6,9E-02
	7,0E-01
	3,4E-01
	5,9E-01
	6,8E-01
	6,6E-01
	9,2E-01

2,9E-02

7,9E-02

3,9E-01

3,2E-01

4,5E-01

5,9E-01

7,3E-01

4,0E-02

2,9E-01

8,3E-02

2,9E-01

2,2E-01

6,7E-02

1,1E-01

8,2E-02

2,2E-01

5,6E-01

2,5E-01

1,2E-01

4,7E-02

5,4E-03

7,0E-03

5,5E-06

9,7E-04

1,0E-02

6,2E-02

1,1E-02

8,1E-01

1,1E-02

1,9E-03

1,0E-02

4,3E-02

2,6E-03

3,6E-03

3,4E-03

2,3E-03

1,2E-02

1,6E-01

2,3E-01

2,1E-04

7,2E-02

3,4E-02

6,1E-03

5,0E-03

2,4E-01

2,2E-04

9,7E-01

9,8E-02

1,1E-01

8,6E-03

2,8E-01

2,0E-03

2,9E-21

5,0E-01

8,8E-01

2,3E-02

2,5E-01

1,8E-01

1,2E-01

2,1E-02

4,9E-01

1,3E-01

4,2E-01

5,0E-01

2,7E-03

3,4E-03

5,1E-02

6,3E-01

6,5E-01

3,4E-01

2,0E-02